| 研究課題/領域番号 |
22KF0089
|
|---|
| 補助金の研究課題番号 |
22F22024 (2022)
|
|---|
| 研究種目 |
特別研究員奨励費
|
| 配分区分 | 基金 (2023)
補助金 (2022) |
|---|
| 応募区分 | 外国 |
|---|
| 審査区分 |
小区分37020:生物分子化学関連
|
|---|
| 研究機関 | 東京大学 |
|---|
研究代表者 |
菅 裕明 東京大学, 大学院理学系研究科(理学部), 教授 (00361668)
|
|---|
| 研究分担者 |
COLAS KILIAN 東京大学, 大学院理学系研究科(理学部), 外国人特別研究員
|
|---|
| 研究期間 (年度) |
2023-03-08 – 2024-03-31
|
| 研究課題ステータス |
完了 (2023年度)
|
| 配分額 *注記 |
2,300千円 (直接経費: 2,300千円)
2023年度: 1,100千円 (直接経費: 1,100千円)
2022年度: 1,200千円 (直接経費: 1,200千円)
|
|---|
| キーワード | protein engineering / grafting / KRas / peptide / lasso-graft / macrocylic peptides / RaPID |
|---|
| 研究開始時の研究の概要 |
In fiscal year 2023, we will focus on addressing the drug delivery issue via viral vectors. By December 2023, we hope to have drug candidates ready for further clinical evaluation and a first proof-of-concept publication. Thereafter, further fine-tuning of the lead candidate, and development of new generation of compounds against other currently undruggable targets will be pursued.
|
| 研究実績の概要 |
We have identified 20 lasso-grafted peptides, termed “Ubodies”, that target one of the major cancer-drivers, KRas(G12D). Some compounds bind to the protein target with high selectivity towards the cancer-driver “on” state of KRas vs its “off” state; while others are selective towards the mutant form vs its wildtype parent (some compounds exhibit dual selectivity). These Ubodies thus have high potential as therapeutic candidates with very little side-effects. Furthermore, we have also developed a new method to identify de novo highly potent Ubodies without the need for a previous binding peptide, which we are currently applying to other cancer targets. We have also started investigating drug delivery avenues (lipid nanoparticles & gene delivery), and early protocols are being validated.
|
